Dabral N, Burcham G, Jain-Gupta N, Sriranganathan N, Vemulapalli R
PLoS One. 2019; 14(3):e0213587.
PMID: 30856219
PMC: 6411116.
DOI: 10.1371/journal.pone.0213587.
Vassen V, Valotteau C, Feuillie C, Formosa-Dague C, Dufrene Y, De Bolle X
EMBO J. 2019; 38(5).
PMID: 30635335
PMC: 6396147.
DOI: 10.15252/embj.2018100323.
Bundle D, McGiven J
Acc Chem Res. 2017; 50(12):2958-2967.
PMID: 29219305
PMC: 5738633.
DOI: 10.1021/acs.accounts.7b00445.
Mandal S, Duncombe L, Ganesh N, Sarkar S, Howells L, Hogarth P
ACS Cent Sci. 2017; 3(3):224-231.
PMID: 28386600
PMC: 5364457.
DOI: 10.1021/acscentsci.7b00019.
Silbereisen A, Tamborrini M, Wittwer M, Schurch N, Pluschke G
BMC Microbiol. 2015; 15:198.
PMID: 26438077
PMC: 4595103.
DOI: 10.1186/s12866-015-0534-1.
Monoclonal Antibody-Defined Specific C Epitope of Brucella O-Polysaccharide Revisited.
Zygmunt M, Bundle D, Ganesh N, Guiard J, Cloeckaert A
Clin Vaccine Immunol. 2015; 22(8):979-82.
PMID: 26063236
PMC: 4519723.
DOI: 10.1128/CVI.00225-15.
Immunogenic and invasive properties of Brucella melitensis 16M outer membrane protein vaccine candidates identified via a reverse vaccinology approach.
Gomez G, Pei J, Mwangi W, Adams L, Rice-Ficht A, Ficht T
PLoS One. 2013; 8(3):e59751.
PMID: 23533646
PMC: 3606113.
DOI: 10.1371/journal.pone.0059751.
Lipopolysaccharide heterogeneity in the atypical group of novel emerging Brucella species.
Zygmunt M, Jacques I, Bernardet N, Cloeckaert A
Clin Vaccine Immunol. 2012; 19(9):1370-3.
PMID: 22761298
PMC: 3428386.
DOI: 10.1128/CVI.00300-12.
What have we learned from brucellosis in the mouse model?.
Grillo M, Blasco J, Gorvel J, Moriyon I, Moreno E
Vet Res. 2012; 43:29.
PMID: 22500859
PMC: 3410789.
DOI: 10.1186/1297-9716-43-29.
Course of infection with the emergent pathogen Brucella microti in immunocompromised mice.
Jimenez De Bagues M, de Martino A, Quintana J, Alcaraz A, Pardo J
Infect Immun. 2011; 79(10):3934-9.
PMID: 21825066
PMC: 3187271.
DOI: 10.1128/IAI.05542-11.
Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge.
Moustafa D, Garg V, Jain N, Sriranganathan N, Vemulapalli R
Vaccine. 2010; 29(4):784-94.
PMID: 21109033
PMC: 3014444.
DOI: 10.1016/j.vaccine.2010.11.018.
Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine.
Bhattacharjee A, Izadjoo M, Zollinger W, Nikolich M, Hoover D
Infect Immun. 2006; 74(10):5820-5.
PMID: 16988260
PMC: 1594895.
DOI: 10.1128/IAI.00331-06.
Fc-dependent polyclonal antibodies and antibodies to outer membrane proteins A and B, but not to lipopolysaccharide, protect SCID mice against fatal Rickettsia conorii infection.
Feng H, Whitworth T, Olano J, Popov V, Walker D
Infect Immun. 2004; 72(4):2222-8.
PMID: 15039346
PMC: 375156.
DOI: 10.1128/IAI.72.4.2222-2228.2004.
Passive antibody administration (immediate immunity) as a specific defense against biological weapons.
Casadevall A
Emerg Infect Dis. 2002; 8(8):833-41.
PMID: 12141970
PMC: 3369592.
DOI: 10.3201/eid0808.010516.
Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen.
Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, Letesson J
Infect Immun. 2002; 70(4):1915-23.
PMID: 11895955
PMC: 127831.
DOI: 10.1128/IAI.70.4.1915-1923.2002.
Antibody-mediated elimination of the obligate intracellular bacterial pathogen Ehrlichia chaffeensis during active infection.
Winslow G, Yager E, Shilo K, VOLK E, Reilly A, Chu F
Infect Immun. 2000; 68(4):2187-95.
PMID: 10722619
PMC: 97403.
DOI: 10.1128/IAI.68.4.2187-2195.2000.
Interaction of Brucella abortus lipopolysaccharide with major histocompatibility complex class II molecules in B lymphocytes.
Forestier C, Moreno E, Meresse S, Phalipon A, Olive D, Sansonetti P
Infect Immun. 1999; 67(8):4048-54.
PMID: 10417173
PMC: 96700.
DOI: 10.1128/IAI.67.8.4048-4054.1999.
O-Polysaccharide epitopic heterogeneity at the surface of Brucella spp. studied by enzyme-linked immunosorbent assay and flow cytometry.
Cloeckaert A, Weynants V, Godfroid J, Verger J, Grayon M, Zygmunt M
Clin Diagn Lab Immunol. 1998; 5(6):862-70.
PMID: 9801349
PMC: 96216.
DOI: 10.1128/CDLI.5.6.862-870.1998.
Characterization of smooth lipopolysaccharides and O polysaccharides of Brucella species by competition binding assays with monoclonal antibodies.
Weynants V, Gilson D, Cloeckaert A, Tibor A, Denoel P, Godfroid F
Infect Immun. 1997; 65(5):1939-43.
PMID: 9125584
PMC: 175246.
DOI: 10.1128/iai.65.5.1939-1943.1997.
Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.
Van De Verg L, Hartman A, Bhattacharjee A, Tall B, Yuan L, Sasala K
Infect Immun. 1996; 64(12):5263-8.
PMID: 8945575
PMC: 174517.
DOI: 10.1128/iai.64.12.5263-5268.1996.